WIKINGO Proyect Systematic Analysis

Tables & Figures.

Proyecto Vikingo September 29, 2016

proyectovikingo@proyectovikingo.es

Contents

•	• ,	C	CD 1	
П.	1St.	Ωt	Tah	IPS

1	Participant characteristics	:
2	According to Local Recurrence	
3	According to Metastasis	
4	According to Exitus	
5	Incidence by outcome [95% CI]	
List	of Figures	
\mathbf{List}		ŗ
\mathbf{List}	Local Recurrence	
1	Local Recurrence	7
$\begin{array}{c} 1 \\ 2 \end{array}$	Local Recurrence	9
1 2 3	Local Recurrence	7 9 10

Table 1: Participant characteristics

ГАТТ	1	
[ALI	•	N
N=27		
Age	$68.4\ (11.2)$	273
Sex: Men	182~(66.7%)	273
Tumor level:		273
0-6cm	95 (34.8%)	
7-12cm	$121\ (44.3\%)$	
$13\text{-}15\mathrm{cm}$	$57\ (20.9\%)$	
Tumor stage:		273
0	14 (5.13%)	
I	90 (33.0%)	
II	77 (28.2%)	
III	92(33.7%)	
Neoadjuvant treatment	141 (51.6%)	273
Type of resection:	,	273
Abdominoperineal resection	50 (18.3%)	
Anterior resection	191 (70.0%)	
Hartmann	32 (11.7%)	
Perforation	23 (8.42%)	273
Invasion circumferential margin	21~(7.69%)	273
Mesorrecto quality:	,	272
Satisfactory	187 (68.8%)	
Partial	41 (15.1%)	
No-satisfactory	44 (16.2%)	
Recidive	12 (4.40%)	273
Months to recidive	16.0 [1.00;36.0]	273
Metastasis	$34 \ (12.5\%)$	273
Months to Metastasis	14.0 [1.00;34.0]	273
Exitus	55 (20.1%)	273
Months to exitus	16.0 [1.00;36.0]	273

Table 2: According to Local Recurrence

			Crude		Multivariat	te	
	No event n= 261	Event n= 12	HR	p-value	HR	p-value	N
Age (10y)	6.86 (1.08)	6.42 (1.78)	0.71 [0.44;1.14]	0.152	0.58 [0.32; 1.06]	0.078	273
Sex: Men	$171 \ (65.5\%)$	11 (91.7%)	5.33 [0.69;41.3]	0.109	6.67 [0.78; 56.84]	0.083	273
Tumor level:	, ,	,					273
0-6cm	89 (34.1%)	6 (50.0%)	3.43 [0.41;28.5]	0.254	7.07 [0.53; 93.61]	0.138	
7-12cm	116 (44.4%)	5 (41.7%)	2.73 [0.32;23.4]	0.359	5.58 [0.53; 59.16]	0.153	
Tumor stage:							273
0	13 (4.98%)	1 (8.33%)	4.67 [0.29;74.6]	0.276	9.12 [0.46;179.12]	0.146	
II	73~(28.0%)	4 (33.3%)	4.85 [0.54;43.4]	0.158	7.58 [0.73; 78.87]	0.09	
III	86 (33.0%)	6 (50.0%)	6.94 [0.83;57.7]	0.073	4.72 [0.52; 42.96]	0.169	
Neoadjuvant treatment	136 (52.1%)	5(41.7%)	$0.80 \ [0.25; 2.51]$	0.699	0.40 [0.10; 1.68]	0.211	273
Type of resection:							273
Abdominoperineal resection	47 (18.0%)	3(25.0%)	1.38 [0.36; 5.35]	0.640	0.56 [0.09; 3.46]	0.528	
Hartmann	30 (11.5%)	2~(16.7%)	4.80 [0.98;23.4]	0.053	6.31 [1.01; 39.49]	0.049	
Perforation	21~(8.05%)	2~(16.7%)	2.28 [0.50;10.4]	0.286	1.16 [0.19; 6.89]	0.873	273
Invasion circumferential margin	19 (7.28%)	2~(16.7%)	2.18 [0.48; 9.94]	0.315	1.02 [0.15; 6.75]	0.985	273
Mesorrecto quality:							272
Partial	$40 \ (15.4\%)$	1~(8.33%)	$0.69 \ [0.09; 5.50]$	0.724	0.65 [0.07; 5.63]	0.692	
No-satisfactory	41 (15.8%)	3(25.0%)	1.89 [0.50;7.14]	0.346	1.16 [0.23; 5.71]	0.858	

Reference categories:

- Age, a decade
- Sex, Women
- \bullet Tumor level, 13-15cm
- $\bullet~$ Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- $\bullet\,$ Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 1: Local Recurrence




Table 3: According to Metastasis

			Crude		Multivariate		
	No event n= 239	Event n= 34	HR	p-value	HR	p-value	N
Age (10y)	6.88 (1.10)	6.52 (1.19)	0.77 [0.58;1.02]	0.067	0.77 [0.55; 1.08]	0.135	273
Sex: Men	156 (65.3%)	26 (76.5%)	$1.63 \ [0.74; 3.60]$	0.229	1.08 [0.45; 2.59]	0.864	273
Tumor level:	,	,	. , ,		. , ,		273
$0\text{-}6\mathrm{cm}$	81 (33.9%)	14 (41.2%)	1.18 [0.48;2.93]	0.718	0.96 [0.25; 3.71]	0.957	
7-12cm	108 (45.2%)	13 (38.2%)	0.97 [0.39; 2.44]	0.955	0.70 [0.25; 1.95]	0.496	
Tumor stage:							273
0	13 (5.44%)	1(2.94%)	1.16 [0.13;10.4]	0.894	0.86 [0.09; 8.48]	0.897	
II	68~(28.5%)	9~(26.5%)	2.98 [0.92;9.67]	0.070	2.57 [0.75; 8.83]	0.133	
III	72 (30.1%)	20~(58.8%)	6.86[2.34;20.1]	< 0.001	5.03 [1.59;15.94]	0.006	
Neoadjuvant treatment	124 (51.9%)	17 (50.0%)	1.17 [0.60; 2.30]	0.644	1.79 [0.79; 4.05]	0.164	273
Type of resection:							273
Abdominoperineal resection	$41\ (17.2\%)$	9(26.5%)	1.55 [0.70; 3.40]	0.279	1.20 [0.35; 4.09]	0.765	
Hartmann	27 (11.3%)	5(14.7%)	5.26 [1.95;14.2]	0.001	11.67 [3.50;38.97]	< 0.001	
Perforation	19~(7.95%)	4~(11.8%)	1.63 [0.57; 4.63]	0.360	0.45 [0.13; 1.51]	0.195	273
Invasion circumferential margin	12 (5.02%)	9~(26.5%)	5.31 [2.48;11.4]	< 0.001	4.16 [1.63;10.63]	0.003	273
Mesorrecto quality:							272
Partial	35~(14.7%)	6~(17.6%)	1.62 [0.66; 3.99]	0.292	1.88 [0.73; 4.83]	0.189	
No-satisfactory	39 (16.4%)	5 (14.7%)	1.19 [0.45;3.14]	0.722	0.96 [0.33; 2.81]	0.944	

Reference categories:

- $\bullet\,$ Age, a decade
- $\bullet~$ Sex, Women
- \bullet Tumor level, 13-15cm
- $\bullet~$ Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 2: Metastasis




Table 4: According to Exitus

			Crude		Multivaria	te	
	No event $n=218$	Event $n=55$	HR	p-value	HR	p-value	N
Age (10y)	6.78 (1.10)	7.04 (1.15)	1.26 [0.96;1.64]	0.090	1.30 [0.96; 1.76]	0.094	273
Sex: Men	$141 \ (64.7\%)$	41 (74.5%)	1.49 [0.81;2.74]	0.195	1.41 [0.74; 2.68]	0.295	273
Tumor level:	, , ,	, , , ,			-		273
0-6cm	72(33.0%)	23~(41.8%)	1.53 [0.71; 3.31]	0.280	2.39 [0.86; 6.63]	0.095	
7-12cm	$98 \ (45.0\%)$	23~(41.8%)	1.37 [0.63; 2.96]	0.428	1.25 [0.52; 2.99]	0.623	
Tumor stage:							273
0	$11 \ (5.05\%)$	3 (5.45%)	1.24 [0.35; 4.40]	0.739	1.42 [0.38; 5.31]	0.598	
II	$62\ (28.4\%)$	15~(27.3%)	1.52 [0.71; 3.24]	0.283	1.48 [0.64; 3.41]	0.358	
III	67 (30.7%)	25~(45.5%)	2.45 [1.23;4.89]	0.011	2.17 [0.98; 4.78]	0.055	
Neoadjuvant treatment	112 (51.4%)	29 (52.7%)	1.28 [0.75; 2.18]	0.363	1.53 [0.82; 2.88]	0.185	273
Type of resection:							273
Abdominoperineal resection	39 (17.9%)	$11\ (20.0\%)$	1.09 [0.55; 2.16]	0.806	0.63 [0.25; 1.56]	0.317	
Hartmann	21 (9.63%)	11 (20.0%)	5.50 [2.68;11.3]	< 0.001	5.00 [2.10;11.90]	< 0.001	
Perforation	15~(6.88%)	8 (14.5%)	1.92 [0.90;4.06]	0.090	1.06 [0.45; 2.50]	0.903	273
Invasion circumferential margin	$10 \ (4.59\%)$	11 (20.0%)	2.96 [1.52;5.77]	0.001	3.14 [1.39; 7.12]	0.006	273
Mesorrecto quality:							272
Partial	32 (14.7%)	9 (16.7%)	1.34 [0.65; 2.77]	0.432	1.35 [0.64; 2.86]	0.427	
No-satisfactory	37 (17.0%)	7 (13.0%)	$1.01 \ [0.45; 2.28]$	0.976	$0.53 \ [0.21; \ 1.34]$	0.181	

Reference categories:

- Age, a decade
- Sex, Women
- \bullet Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- $\bullet\,$ Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 3: Exitus




Figure 4: Local Recurrence, according to Type of Resection:







Figure 5: Metastasis, according to Type of Resection:



Ant

Н

Figure 6: Survival, according to Type of Resection:




Table 5: Incidence by outcome [95% CI]

Months	Local Recurrence	Metastasis	Exitus
12	2.81 [5.2; 0.35]	9.48 [13.67; 5.09]	9.87 [13.76; 5.82]
24	6.87 [10.73; 2.83]	16.45 [22.02; 10.49]	18.97 [24.43; 13.12]
36	7.67 [11.8; 3.35]	23.64 [30.67; 15.89]	28.09 [34.92; 20.54]
48	7.67 [11.8; 3.35]	23.64 [30.67; 15.89]	38.3 [46.97; 28.2]
60	7.67 [11.8; 3.35]	23.64 [30.67; 15.89]	38.3 [46.97; 28.2]